Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma

Trial Profile

A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivosidenib (Primary) ; Vorasidenib (Primary)
  • Indications Astrocytoma; Glioma; Oligodendroglioma
  • Focus Biomarker; Pharmacodynamics
  • Acronyms Window
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 22 Nov 2019 Results published in Agios Pharmaceuticals Media Release (July 26, 2019 data cutoff)
    • 22 Nov 2019 According to an Agios Pharmaceuticals media release, data from this study was featured in an oral presentation at the Society for Neuro-Oncology (SNO) Annual Meeting in Phoenix.
    • 30 Aug 2019 Planned End Date changed from 1 Sep 2020 to 1 May 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top